
RxSight (RXST) Stock Forecast & Price Target
RxSight (RXST) Analyst Ratings
Bulls say
RxSight is a commercial-stage medical technology company that offers intraocular lens technology for cataract surgery. Despite a decline in utilization and margin contraction in the last quarter, the company has seen early successes in its commercial strategy and expects to return to growth in the second half of 2026. With a strong management team, achievable guidance, and undemanding valuation, analysts maintain a Buy rating for the stock.
Bears say
RxSight is facing challenges with declining revenue and increased losses, as indicated in the recent results where revenue and earnings missed expectations and guidance for the future was also weaker than expected. The company's growth is also heavily reliant on LAL technology, which may face competition and reimbursement challenges. Additionally, the company's continued cash burn could be a concern for investors.
This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.
RxSight (RXST) Analyst Forecast & Price Prediction
Start investing in RxSight (RXST)
Order type
Buy in
Order amount
Est. shares
0 shares